SCENARIO 3 — MLO 3.3 — Read carefully before answering Quest…
SCENARIO 3 — MLO 3.3 — Read carefully before answering Questions 9 through 12. A pharmaceutical company is deciding whether to fast-track a new drug through regulatory approval. Four people have significant influence over the decision: the CEO (who controls resource allocation and sets the company agenda), the Chief Medical Officer (a world-renowned researcher whose clinical judgment is trusted across the industry), the Head of Regulatory Affairs (who can withhold sign-off required for any FDA submission), and a senior sales manager (who has worked with most of the key hospital accounts for 20 years and is deeply respected by the field team). QUESTION 9 OF 4: Which power base BEST describes the Chief Medical Officer’s influence in this decision?
Read DetailsSCENARIO 1 CONTINUED — QUESTION 3 OF 4: The administrator al…
SCENARIO 1 CONTINUED — QUESTION 3 OF 4: The administrator also considers using the Nominal Group Technique for the next major committee decision. Which statement BEST describes what the Nominal Group Technique is designed to do?
Read DetailsSCENARIO 3 CONTINUED — Under significant time pressure, the…
SCENARIO 3 CONTINUED — Under significant time pressure, the CEO calls for a vote. The CMO recommends proceeding with modifications to address the regulatory concerns. The group agrees — not because everyone is fully satisfied, but because the CMO’s proposal is acceptable to all parties and continuing to debate risks missing the market window entirely. QUESTION 12 OF 4: Which concept BEST describes the group’s decision-making process in this moment?
Read Details